SCHEMBL13612949

SCHEMBL13612949

CC(=O)CN(C=O)c1ccc(C)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 2/20 0.34
SRC P12931 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12913757 0.84 LMNA (0.35) KDM4EMEN1KMT2AMAPTMAPK1
SCHEMBL12157436 0.82 HPGD (0.41) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL28545430 0.72 CACNA2D1 (0.43) KDM4ESMN1; SMN2MEN1KMT2AMAPT
Formic Acid SCHEMBL28902054 0.71 ALDH1A3 (0.44) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL17723416 0.70 APOBEC3A (0.35) KDM4ESMN1; SMN2MEN1KMT2ANPC1
SCHEMBL11422284 0.70 GAA (0.45) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL10866707 0.70 CYP3A4 (0.40) KDM4ESMN1; SMN2MEN1KMT2AHTT
SCHEMBL341221 0.69 KEAP1 (0.46) KDM4ESMN1; SMN2MEN1KMT2ATSHR
SCHEMBL8058674 0.69 GAA (0.33) MEN1KMT2AALOX15ALDH1A1LMNA
SCHEMBL3973298 0.69 TSHR (0.39) KDM4ESMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618960-B2 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-17 US disclosed
US-20070117798-A1 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117798-A1 Morpholine type cinnamide compound MLX, XDH, NOX4 KDM4E 2077/4885SMN1; SMN2 642/4885MEN1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.